Opendata, web and dolomites


The first predictive test for radio-sensitivity. A step towards an improved and personalised radiation therapy cancer treatment.

Total Cost €


EC-Contrib. €






 NovaTests project word cloud

Explore the words cloud of the NovaTests project. It provides you a very rough idea of what is the project "NovaTests" about.

efficient    evidences    sensitive    indiscriminately    week    efficiency    fits    directive    healthy    centre    validation    robustness    invested    undergo    scientific    financial    stamped    pertaining    vitro    damaging    90    sme    automating    treatment    instrument    accuracy    each    therapy    survivors    move    5m    stage    active    blood    tests    cancers    sensitivity    diagnostic    tumour    patients    quality    million    ongoing    2016    rest    cancer    link    tailor    reliability    deployment    novagray    novatests    biology    vary    radio    prostate    direct    close    2m    medical    market    measuring    unmet    tolerance    radiation    sound    february    run    trial    breast    prove    ce    analysing    meets    79    validate    first    patient    cells    radiotherapy    clinical    lives    98    fast    lung    time    marking    reg    tissues    intend    predictive    radiosensitivity    extension    serious    organs    regulatory    treatments    significantly    plan   

Project "NovaTests" data sheet

The following table provides information about the project.


Organization address
postcode: 34960
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2018-09-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NOVAGRAY FR (MONTPELLIER) coordinator 50˙000.00


 Project objective

Each year, two out of three cancer patients undergo radiation therapy, meaning close to 1.5M patients in Europe and 2M in the US. However, scientific evidences prove a direct link between radiation therapy and several serious late effects. This because patient’s tolerance to radiation vary significantly and radiotherapy affects indiscriminately both healthy and cancer cells, damaging also active working cells, tissues or organs around the tumour. There is, therefore, an unmet clinical need to tailor treatments to each patient’s unique biology. NovaTests are the first predictive radio-sensitivity tests for cancer treatment. By analysing a simple blood sample, in one week time, we can determine with high accuracy (over 90%) not only whether a patient is sensitive or not to radiation but also how sensitive the patient is. We allow for more efficient treatments and improved quality of cancer survivors, not only during radiation treatments but for the rest of their lives. Our first test, the NovaGray Breast® is aimed at measuring radiosensitivity for breast cancer patients. It meets all regulatory requirements of the 98/79 directive pertaining to the in-vitro diagnostic medical devices, has been stamped with the CE marking in February 2016. So far, €0.5M million have been invested into the development and testing of technology to ensure its robustness and efficiency and move into the next stage of tests development and validation. Within the overall project, we intend to scale-up the process by automating it and run a multi-centre clinical trial to validate the reliability of the test. Further ongoing developments include the extension of the technology to prostate and lung cancers. The proposed work in Phase 1 of the SME instrument fits into our overall plan to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of NovaTests and their market uptake.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOVATESTS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NOVATESTS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ARON (2020)

Assay-Ready Organ Network

Read More  

IMPACT (2019)

Improving DNA Analysis for Correct Healthcare

Read More  

VACTEC (2019)

VACTEC_Responsive corrosion inhibiting Vacuum Technology-based fire protection system

Read More